💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rosuvastatin

CHEMBL1496 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
19 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
481.5 g/mol
LogP
1.6
Phase
4

A potent statin medication used to lower LDL cholesterol and triglycerides while raising HDL cholesterol, significantly reducing the risk of heart attack, stroke, and other cardiovascular events. It is generally well-tolerated and effective at low doses, making it one of the most widely prescribed cholesterol-lowering medications.

น้ำหนักโมเลกุล

481.5390 g/mol

LogP

1.60

TPSA

149.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Glaucoma Cardiovascular Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Parkinson's Disease Melanoma Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Hyperlipidemia Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Malaria HIV/AIDS Hepatitis C Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

หมวดหมู่ยา

C — C - Cardiovascular System

กลไกการออกฤทธิ์

Competitive inhibitor of HMG-CoA reductase.

Pharmacokinetics (PK)

Half-Life 19 hours

Pharmacodynamics (PD)

กลไก

Competitive inhibitor of HMG-CoA reductase.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H28FN3O6S

                    

                    
                    

                        
HBD / HBA

                        
3 / 10

                    

                    
                    

                        
พันธะที่หมุนได้

                        
10

                    

                    
                    
                    

                        
อะตอมหนัก

                        
33

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            HMGCR (HMG-CoA Reductase)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Rosuvastatin + Warfarin
                            
                        

                        
                        
Rosuvastatin increases warfarin plasma concentrations through inhibition of CYP2C9, potentially leading to supratherapeutic INR values.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Rosuvastatin + Colchicine
                            
                        

                        
                        
Rosuvastatin and colchicine share BCRP transporter-mediated elimination; colchicine may weakly increase rosuvastatin exposure, and both carry myotoxic potential that could be additive.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
A potent statin medication used to lower LDL cholesterol and triglycerides while raising HDL cholesterol, significantly reducing the risk of heart attack, stroke, and other cardiovascular events. It is generally well-tolerated and effective at low doses, making it one of the most widely prescribed cholesterol-lowering medications.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitive inhibitor of HMG-CoA reductase.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Rosuvastatin: Half-life: 19 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Rosuvastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1496.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 446157.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.